vs

Side-by-side financial comparison of enCore Energy Corp. (EU) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

enCore Energy Corp. is the larger business by last-quarter revenue ($12.4M vs $6.6M, roughly 1.9× Lineage Cell Therapeutics, Inc.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -173.9%, a 186.8% gap on every dollar of revenue. enCore Energy Corp. produced more free cash flow last quarter ($7.2M vs $-5.3M).

Devon Energy Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware with operational headquarters in the 50-story Devon Energy Center in Oklahoma City, Oklahoma. Its operations are in the Delaware Basin, Eagle Ford Group, and the Rocky Mountains.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

EU vs LCTX — Head-to-Head

Bigger by revenue
EU
EU
1.9× larger
EU
$12.4M
$6.6M
LCTX
Higher net margin
LCTX
LCTX
186.8% more per $
LCTX
12.9%
-173.9%
EU
More free cash flow
EU
EU
$12.4M more FCF
EU
$7.2M
$-5.3M
LCTX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EU
EU
LCTX
LCTX
Revenue
$12.4M
$6.6M
Net Profit
$-21.5M
$851.0K
Gross Margin
37.9%
Operating Margin
-135.9%
-99.1%
Net Margin
-173.9%
12.9%
Revenue YoY
130.4%
Net Profit YoY
126.0%
EPS (diluted)
$-0.11
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EU
EU
LCTX
LCTX
Q4 25
$12.4M
$6.6M
Q3 25
$8.9M
$3.7M
Q2 25
$3.7M
$2.8M
Q1 25
$18.2M
$1.5M
Q4 24
$2.9M
Q3 24
$3.8M
Q2 24
$1.4M
Q1 24
$1.4M
Net Profit
EU
EU
LCTX
LCTX
Q4 25
$-21.5M
$851.0K
Q3 25
$-4.8M
$-29.8M
Q2 25
$-6.3M
$-30.5M
Q1 25
$-24.2M
$-4.1M
Q4 24
$-3.3M
Q3 24
$-3.0M
Q2 24
$-5.8M
Q1 24
$-6.5M
Gross Margin
EU
EU
LCTX
LCTX
Q4 25
37.9%
Q3 25
43.8%
Q2 25
30.8%
Q1 25
-0.1%
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Q1 24
93.2%
Operating Margin
EU
EU
LCTX
LCTX
Q4 25
-135.9%
-99.1%
Q3 25
-158.2%
-102.9%
Q2 25
-526.1%
-715.4%
Q1 25
-85.7%
-433.1%
Q4 24
-178.2%
Q3 24
-101.6%
Q2 24
-416.7%
Q1 24
-461.3%
Net Margin
EU
EU
LCTX
LCTX
Q4 25
-173.9%
12.9%
Q3 25
-53.7%
-809.0%
Q2 25
-172.7%
-1101.8%
Q1 25
-132.9%
-275.6%
Q4 24
-114.1%
Q3 24
-80.3%
Q2 24
-409.1%
Q1 24
-453.0%
EPS (diluted)
EU
EU
LCTX
LCTX
Q4 25
$-0.11
$0.00
Q3 25
$-0.03
$-0.13
Q2 25
$-0.03
$-0.13
Q1 25
$-0.13
$-0.02
Q4 24
$0.00
Q3 24
$-0.02
Q2 24
$-0.03
Q1 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EU
EU
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$52.4M
$55.8M
Total DebtLower is stronger
$110.0M
Stockholders' EquityBook value
$229.2M
$44.5M
Total Assets
$430.4M
$112.6M
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EU
EU
LCTX
LCTX
Q4 25
$52.4M
$55.8M
Q3 25
$91.9M
$40.5M
Q2 25
$26.9M
$42.3M
Q1 25
$29.7M
$47.9M
Q4 24
$47.8M
Q3 24
$32.7M
Q2 24
$38.5M
Q1 24
$43.6M
Total Debt
EU
EU
LCTX
LCTX
Q4 25
$110.0M
Q3 25
$109.3M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EU
EU
LCTX
LCTX
Q4 25
$229.2M
$44.5M
Q3 25
$248.6M
$22.0M
Q2 25
$264.7M
$48.4M
Q1 25
$267.9M
$79.0M
Q4 24
$78.4M
Q3 24
$66.2M
Q2 24
$68.3M
Q1 24
$72.4M
Total Assets
EU
EU
LCTX
LCTX
Q4 25
$430.4M
$112.6M
Q3 25
$441.9M
$89.6M
Q2 25
$359.4M
$90.8M
Q1 25
$362.6M
$111.8M
Q4 24
$113.2M
Q3 24
$96.6M
Q2 24
$102.8M
Q1 24
$108.5M
Debt / Equity
EU
EU
LCTX
LCTX
Q4 25
0.48×
Q3 25
0.44×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EU
EU
LCTX
LCTX
Operating Cash FlowLast quarter
$12.9M
$-4.9M
Free Cash FlowOCF − Capex
$7.2M
$-5.3M
FCF MarginFCF / Revenue
57.8%
-79.9%
Capex IntensityCapex / Revenue
46.7%
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-45.0M
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EU
EU
LCTX
LCTX
Q4 25
$12.9M
$-4.9M
Q3 25
$-20.3M
$-3.6M
Q2 25
$-9.9M
$-5.5M
Q1 25
$-7.7M
$-4.9M
Q4 24
$-6.3M
Q3 24
$-5.8M
Q2 24
$-5.2M
Q1 24
$-5.8M
Free Cash Flow
EU
EU
LCTX
LCTX
Q4 25
$7.2M
$-5.3M
Q3 25
$-26.3M
$-3.6M
Q2 25
$-14.1M
$-5.6M
Q1 25
$-11.7M
$-5.0M
Q4 24
$-6.7M
Q3 24
$-5.9M
Q2 24
$-5.2M
Q1 24
$-5.8M
FCF Margin
EU
EU
LCTX
LCTX
Q4 25
57.8%
-79.9%
Q3 25
-296.6%
-98.6%
Q2 25
-385.2%
-200.8%
Q1 25
-64.1%
-331.8%
Q4 24
-234.0%
Q3 24
-156.1%
Q2 24
-371.2%
Q1 24
-403.1%
Capex Intensity
EU
EU
LCTX
LCTX
Q4 25
46.7%
6.0%
Q3 25
68.0%
0.3%
Q2 25
115.1%
0.5%
Q1 25
21.7%
6.5%
Q4 24
12.7%
Q3 24
3.0%
Q2 24
3.6%
Q1 24
2.6%
Cash Conversion
EU
EU
LCTX
LCTX
Q4 25
-5.73×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EU
EU

Segment breakdown not available.

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons